Women with stage I to III hormone receptor–positive breast cancer should consider taking tamoxifen for 10 years, the American Society of Clinical Oncology (ASCO) says in a clinical practice guideline focused update.
The guideline, Adjuvant Endocrine Therapy for Women with Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update, was published online in the Journal of Clinical Oncology on May 27. It replaces ASCO's 2010 guideline update.
No comments:
Post a Comment